TOP2A (Ab-1343) Antibody

What is TOP2A (Ab-1343) Antibody and what specific epitope does it recognize?

TOP2A (Ab-1343) Antibody is a rabbit polyclonal antibody that specifically recognizes human DNA topoisomerase II alpha (TOP2A) protein. This antibody targets a specific region around the phosphorylation site of threonine 1343 (E-K-T(p)-D-D) in the TOP2A protein sequence. It is generated using a synthesized non-phosphopeptide derived from human TOP2A as the immunogen . This specific epitope recognition allows researchers to detect endogenous levels of total TOP2A protein in experimental samples, making it a valuable tool for studying TOP2A expression and function in various cellular contexts.

What are the validated applications for TOP2A (Ab-1343) Antibody?

The TOP2A (Ab-1343) Antibody has been validated for multiple experimental applications:

The antibody has been validated on multiple cell lines including HepG2 and K562, confirming its specificity and reliability for detecting endogenous TOP2A protein . When designing experiments, researchers should perform optimization tests to determine the ideal antibody concentration for their specific experimental conditions and cell types.

What is the role of TOP2A in cellular processes and why is it important for research?

TOP2A (DNA topoisomerase II alpha) plays critical roles in several fundamental cellular processes:

• DNA replication and transcription: TOP2A resolves DNA topological issues during these processes by creating transient double-strand breaks

• Chromosome condensation and segregation during mitosis

• DNA damage response pathways

• Hematopoietic progenitor cell differentiation

The human TOP2A protein has a canonical length of 1531 amino acids with a molecular weight of approximately 174.4 kDa . It is primarily localized in the nucleus and cytoplasm, with notable expression in tissues such as bone marrow and lymph nodes . TOP2A is particularly important in cancer research due to its role in cell proliferation and as a target for various anticancer drugs, making antibodies against this protein valuable tools for studying cancer biology and therapeutic responses.

What are the optimal storage and handling conditions for maintaining TOP2A (Ab-1343) Antibody activity?

To maintain optimal activity of TOP2A (Ab-1343) Antibody, follow these evidence-based storage and handling recommendations:

• Upon receipt, store the antibody at -20°C or -80°C for long-term storage

• Avoid repeated freeze-thaw cycles as they can denature the antibody and reduce activity

• For working solutions, aliquot the antibody into smaller volumes before freezing to minimize freeze-thaw cycles

• The antibody is supplied in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, containing 150mM NaCl, 0.02% sodium azide, and 50% glycerol

• When handling, use sterile techniques and avoid contamination

Researchers should note that proper storage conditions significantly impact experimental reproducibility. If diminished activity is observed after prolonged storage, validation experiments should be performed before proceeding with critical experiments.

How should western blot protocols be optimized for TOP2A (Ab-1343) Antibody detection?

For optimal western blot detection using TOP2A (Ab-1343) Antibody, consider the following methodological recommendations:

• Sample preparation:

  • Use appropriate lysis buffers containing protease inhibitors

  • Include phosphatase inhibitors if phosphorylation status is relevant

  • Load 20-50 μg of total protein per lane

• Electrophoresis and transfer:

  • Use 6-8% SDS-PAGE gels due to TOP2A's high molecular weight (174 kDa)

  • Transfer at lower voltage for longer periods (e.g., 30V overnight) to ensure complete transfer of high molecular weight proteins

• Antibody incubation:

  • Start with 1:1000 dilution for primary antibody incubation (adjust based on signal intensity)

  • Incubate overnight at 4°C for optimal binding

  • Use 5% BSA in TBST as blocking and antibody dilution buffer

• Signal detection:

  • HepG2 and K562 cell lines have been validated as positive controls

  • For verification of specificity, consider using synthetic peptide blocking experiments as demonstrated in the product data

This antibody has been shown to detect endogenous levels of total TOP2A protein with high specificity, making it suitable for studying TOP2A expression in various research contexts.

What control samples and validation steps should be included when using TOP2A (Ab-1343) Antibody?

To ensure experimental rigor and reproducibility when using TOP2A (Ab-1343) Antibody, incorporate these essential controls and validation steps:

• Positive controls:

  • HepG2 and K562 cell lysates are confirmed to express detectable levels of TOP2A

  • Include tissue samples known to have high TOP2A expression (bone marrow, lymph nodes)

• Negative controls:

  • Primary antibody omission control

  • Isotype control (rabbit IgG at equivalent concentration)

  • Peptide competition assay using the synthesized peptide, as demonstrated in the product data sheet

• Validation experiments:

  • Correlation with mRNA expression data

  • siRNA knockdown to confirm antibody specificity

  • Cross-validation with another TOP2A antibody targeting a different epitope

• Reproducibility measures:

  • Test antibody lot-to-lot variation

  • Document all experimental parameters meticulously

  • Include technical and biological replicates

The peptide competition assay is particularly important for this antibody; pre-incubation of the antibody with the immunizing peptide should abolish the specific signal in western blot, confirming antibody specificity as shown in the K562 cell lysate experiments .

How can TOP2A (Ab-1343) Antibody be employed in cancer research studies?

TOP2A (Ab-1343) Antibody offers several sophisticated applications in cancer research:

• Biomarker analysis:

  • Examine TOP2A expression levels across cancer types and correlate with clinical outcomes

  • Track changes in TOP2A expression during tumor progression and in response to therapy

  • Evaluate phosphorylation status of Thr1343 in different cancer subtypes

• Drug response studies:

  • Monitor TOP2A expression and localization before and after treatment with topoisomerase inhibitors

  • Investigate resistance mechanisms to TOP2A-targeting drugs in patient-derived samples

  • Perform dual staining with proliferation or apoptosis markers to characterize cellular responses

• Cell cycle analysis:

  • Combine with cell cycle markers to study TOP2A expression throughout cell division

  • Investigate phosphorylation-dependent regulation of TOP2A activity using phospho-specific antibodies alongside Ab-1343

• Mechanistic studies:

  • Perform co-immunoprecipitation using TOP2A (Ab-1343) to identify novel interaction partners

  • Investigate TOP2A localization changes during DNA damage response

This antibody's specificity for the region around threonine 1343 makes it particularly valuable for studies investigating post-translational modifications that may influence TOP2A function in cancer cells.

What methodological approaches can resolve common troubleshooting issues when using TOP2A (Ab-1343) Antibody?

When encountering challenges with TOP2A (Ab-1343) Antibody experiments, consider these evidence-based troubleshooting strategies:

• Weak or no signal in Western blot:

  • Increase protein loading (50-100 μg) for low-expressing samples

  • Optimize transfer conditions for high molecular weight proteins (30V overnight)

  • Increase antibody concentration (up to 1:500) or incubation time

  • Use enhanced chemiluminescence (ECL) substrate with increased sensitivity

  • Verify sample preparation - ensure phosphatase inhibitors are included if phosphorylation status affects epitope recognition

• Non-specific bands:

  • Increase blocking time and stringency (5% BSA or milk in TBST)

  • Optimize antibody dilution (try 1:1000-1:3000 range)

  • Include Tween-20 (0.1%) in all washing steps

  • Perform peptide competition assay to identify specific bands

• Inconsistent results between experiments:

  • Standardize lysate preparation protocols

  • Prepare fresh working dilutions of antibody for each experiment

  • Document lot numbers and validate new lots against previous results

  • Control for cell confluence and passage number which may affect TOP2A expression

• Cross-reactivity concerns:

  • Verify species reactivity (confirmed for human, not validated for other species)

  • Test on known negative samples

  • Consider using complementary detection methods (qPCR) to validate expression patterns

These methodological refinements address the most common technical challenges while maintaining experimental rigor.

How does the phosphorylation status at Thr1343 affect TOP2A function and antibody recognition?

The phosphorylation status at threonine 1343 represents an important regulatory mechanism for TOP2A function and may influence antibody recognition:

• Functional implications of Thr1343 phosphorylation:

  • Located in the C-terminal domain of TOP2A, which is involved in nuclear localization and protein-protein interactions

  • Phosphorylation at Thr1343 may regulate TOP2A catalytic activity during cell cycle progression

  • This site may be targeted by specific kinases during DNA damage response or mitosis

• Impact on antibody recognition:

  • TOP2A (Ab-1343) Antibody was raised against a non-phosphopeptide , suggesting it recognizes the unphosphorylated form

  • Phosphorylation at Thr1343 might alter epitope accessibility or antibody binding affinity

  • Researchers investigating phosphorylation-dependent functions should consider using both phospho-specific and total TOP2A antibodies

• Experimental considerations:

  • Treatment with phosphatase inhibitors during sample preparation may affect detected signal intensity

  • Cell cycle synchronization can help standardize phosphorylation status across samples

  • Consider lambda phosphatase treatment of parallel samples to determine if phosphorylation affects antibody recognition

• Research applications:

  • Investigate conditions that induce Thr1343 phosphorylation (e.g., specific cell cycle phases, DNA damage)

  • Compare recognition patterns between phospho-specific and non-phospho-specific antibodies

  • Study the kinases and phosphatases that regulate this specific site

This advanced understanding of the epitope region helps researchers design more precise experiments when investigating TOP2A regulatory mechanisms.

How does TOP2A (Ab-1343) Antibody compare with other TOP2A antibodies for specific research applications?

When selecting the optimal TOP2A antibody for specific research applications, consider these comparative insights:

Research considerations for antibody selection:

This comparative analysis enables researchers to select the most appropriate antibody based on their specific experimental requirements and research questions.

What complementary methods should be combined with TOP2A antibody detection for comprehensive analysis?

For robust and multidimensional analysis of TOP2A biology, integrate antibody-based detection with these complementary methodologies:

• Transcriptional analysis:

  • RT-qPCR to quantify TOP2A mRNA expression

  • RNA-seq for genome-wide expression context

  • Correlation between protein levels (antibody detection) and mRNA expression to identify post-transcriptional regulation

• Functional assays:

  • Topoisomerase activity assays to correlate protein expression with enzymatic function

  • DNA damage assessment (γH2AX staining) to evaluate TOP2A activity in DNA damage response

  • Cell proliferation assays to connect TOP2A expression with cellular outcomes

• Genetic manipulation:

  • CRISPR/Cas9-mediated knockout or knockin experiments

  • siRNA/shRNA knockdown followed by rescue experiments

  • Site-directed mutagenesis of Thr1343 to assess phosphorylation significance

• Advanced imaging techniques:

  • Super-resolution microscopy to visualize TOP2A localization

  • FRET analysis to study protein-protein interactions

  • Live-cell imaging with fluorescently tagged TOP2A to track dynamics

• Clinical correlation:

  • Tissue microarray analysis using validated TOP2A antibodies

  • Correlation with patient outcomes and treatment responses

  • Integration with genomic and transcriptomic data from patient cohorts

This integrated approach yields a more comprehensive understanding of TOP2A biology than antibody-based detection alone, enabling researchers to connect molecular observations with functional outcomes and clinical relevance.

How can researchers integrate TOP2A (Ab-1343) Antibody data with genomic and proteomic datasets?

Integrating TOP2A antibody data with multi-omics approaches enhances research depth and contextualizes findings within broader biological systems:

• Multi-omics integration strategies:

  • Correlate TOP2A protein levels (detected with Ab-1343) with RNA-seq expression data

  • Connect protein expression patterns with TOP2A copy number alterations from genomic data

  • Integrate with phosphoproteomic data to contextualize Thr1343 phosphorylation within the broader signaling network

  • Compare with chromatin immunoprecipitation sequencing (ChIP-seq) data to associate TOP2A binding sites with expression changes

• Computational approaches:

  • Use pathway enrichment analysis to identify processes associated with TOP2A expression changes

  • Apply machine learning algorithms to identify patterns connecting TOP2A expression with other molecular features

  • Develop predictive models incorporating TOP2A protein levels as biomarkers for treatment response

• Database utilization and contribution:

  • Compare findings with cancer genomics databases (TCGA, ICGC)

  • Integrate with protein-protein interaction databases to contextualize TOP2A within its interactome

  • Consider depositing standardized antibody validation data to public repositories

• Translational research applications:

  • Correlate TOP2A protein levels with patient outcomes in clinical datasets

  • Stratify patient samples based on TOP2A expression and phosphorylation status

  • Identify potential synthetic lethal interactions with TOP2A for combination therapy development

This integrative approach transforms descriptive antibody-based data into systems-level insights, enabling researchers to generate novel hypotheses and identify previously unrecognized connections between TOP2A function and broader biological processes.

What are the emerging applications for TOP2A antibodies in precision medicine and biomarker development?

TOP2A antibodies, including Ab-1343, are increasingly valuable in translational research and precision medicine applications:

• Biomarker development:

  • Standardized immunohistochemical protocols using validated TOP2A antibodies for patient stratification

  • Quantitative assessment of TOP2A expression and phosphorylation status as predictive biomarkers for topoisomerase inhibitor response

  • Development of companion diagnostics for TOP2A-targeting therapies

• Liquid biopsy approaches:

  • Detection of circulating tumor cells expressing TOP2A

  • Evaluation of extracellular vesicles containing TOP2A protein

  • Correlation between circulating and tissue-based TOP2A levels

• Targeted therapy development:

  • Screening for compounds that modulate TOP2A expression or activity

  • Investigating synthetic lethality between TOP2A inhibition and other pathways

  • Development of antibody-drug conjugates targeting cancer cells with high TOP2A expression

• Resistance mechanism studies:

  • Using TOP2A antibodies to track expression changes during treatment and relapse

  • Identifying compensatory mechanisms when TOP2A is inhibited

  • Characterizing cancer cell populations with heterogeneous TOP2A expression

These emerging applications reflect the growing importance of TOP2A as both a therapeutic target and a biomarker in personalized cancer treatment approaches.

What methodological advances are needed to improve TOP2A antibody research?

Several methodological advances would significantly enhance TOP2A antibody research and applications:

• Antibody technology improvements:

  • Development of monoclonal antibodies targeting specific TOP2A phosphorylation sites, including Thr1343

  • Generation of conformation-specific antibodies that distinguish between active and inactive TOP2A

  • Creation of antibodies specific to different TOP2A isoforms

  • Production of nanobodies for live-cell imaging applications

• Standardization and validation:

  • Establishment of reference standards for TOP2A detection across laboratories

  • Development of quantitative measurement protocols with defined thresholds

  • Implementation of digital pathology for objective TOP2A quantification

  • Cross-validation protocols across different antibody clones and detection methods

• Technical innovations:

  • Multiplex immunoassays to simultaneously detect TOP2A and interacting proteins

  • Single-cell proteomics approaches to characterize TOP2A expression heterogeneity

  • Advanced imaging technologies for dynamic tracking of TOP2A localization

  • Development of biosensors for real-time monitoring of TOP2A activity

• Reproducibility initiatives:

  • Open-source protocols for standardized TOP2A detection

  • Antibody validation repositories with experimental design guidelines

  • Inter-laboratory studies to establish consensus detection methods

These methodological advances would address current limitations in TOP2A research and enable more sophisticated investigations into its biological functions and clinical significance.

What recent discoveries about TOP2A function might influence experimental design using TOP2A (Ab-1343) Antibody?

Recent advances in understanding TOP2A biology should inform experimental design when using TOP2A (Ab-1343) Antibody:

• Post-translational regulation discoveries:

  • Emerging evidence suggests dynamic phosphorylation patterns throughout the cell cycle

  • Threonine phosphorylation sites, including those near the Ab-1343 epitope region, may regulate TOP2A activity

  • Researchers should consider cell synchronization protocols when studying phosphorylation-dependent regulation

• Non-canonical functions:

  • Beyond its enzymatic activity, TOP2A may function as a structural component in chromosome organization

  • Recent evidence indicates roles in transcriptional regulation independent of its catalytic function

  • Experimental designs should distinguish between enzymatic activity and structural roles

• Subcellular localization insights:

  • Dynamic shuttling between nuclear and cytoplasmic compartments under certain conditions

  • Association with specific nuclear subdomains during different cellular processes

  • Fractionation protocols should be optimized to capture these distribution patterns

• Interaction network expansion:

  • Growing evidence for direct interactions with DNA damage response proteins

  • Associations with chromatin remodeling complexes and transcriptional machinery

  • Co-immunoprecipitation experiments using Ab-1343 may reveal context-specific interaction partners

• Isoform-specific functions:

  • Emerging data on splice variants with potentially distinct functions

  • Researchers should consider isoform specificity when interpreting antibody results